PRKACB
Overview
PRKACB encodes the catalytic beta subunit of cAMP-dependent protein kinase A. In cholangiocarcinoma (CCA), it is recurrently involved in fusions that retain the pseudokinase domain and are proposed to activate MAPK signaling.
Alterations observed in the corpus
- ATP1B1-PRKACB and LINC00261-PRKACB fusions identified in cholangiocarcinoma; both fusions retain the PRKACB pseudokinase domain and are proposed to activate MAPK signaling PMID:28667006
Cancer types (linked)
- CCA: recurrent fusion driver identified in integrative multi-platform genomic study of 489 CCAs PMID:28667006
Co-occurrence and mutual exclusivity
Therapeutic relevance
- PRKACB fusions may represent a therapeutic target via MAPK pathway inhibition, though clinical validation is pending PMID:28667006
Open questions
- Functional validation of MAPK activation by ATP1B1-PRKACB and LINC00261-PRKACB fusions is pending; whether these fusions confer sensitivity to MEK or ERK inhibitors is unknown.
Sources
This page was processed by entity-page-writer on 2026-05-15.